Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021;84(1):43-48.
doi: 10.1159/000512077. Epub 2020 Dec 15.

Exacerbation Rate in Generalized Myasthenia Gravis and Its Predictors

Ahmad R Abuzinadah  1   2 , Mohammed H Alanazy  3 , Nadeem S Butt  4 , Richard J Barohn  5 , Mazen M Dimachkie  5
Affiliations

Exacerbation Rate in Generalized Myasthenia Gravis and Its Predictors

Ahmad R Abuzinadah et al. Eur Neurol. 2021.

Abstract

Objective: The aim of the study was to estimate the exacerbation incidence rate (IR) in acetylcholine receptor antibody (AChR)-positive generalized myasthenia gravis (MG) and its predictors.

Methods: The primary outcome in this retrospective study was to estimate moderate-to-severe (M-S) exacerbations IR in the early course of generalized MG. The secondary outcome was to explore the predictors of MG exacerbations.

Results: Between 1999 and 2015, we identified 78 AChR-positive generalized MG patients and 37 M-S exacerbations over the first 6 years following the onset of generalized MG symptoms. The M-S exacerbation IR was 12.2 per 100 person years (95% confidence interval [CI] 8.8-16.8). Any exacerbation (including mild) IR was 24.4 per 100 person years (95% CI 19.4-30.7). After controlling for confounding factors, MG exacerbation IR predictors included gender, disease severity at onset, and prednisone dose reduction with risk ratio of 0.34 (male gender), 2.67, and 20.8, respectively (all p values <0.05). M-S exacerbation occurred in 25 cases (32.1%), while any exacerbation (mild or M-S) was detected in 45 cases (57.7%).

Conclusion: More than half of newly diagnosed AChR + MG cases experience an exacerbation in the first 6 years. Gender, disease severity at onset and prednisone dose reduction are predictors that could inform clinical practice and future research.

Keywords: Exacerbation; Immunosuppressant; Incidence; Myasthenia gravis; Predictors; Prednisone.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow chart as per CONSORT (Consolidating Standards of Reported Trials) guidelines
See this image and copyright information in PMC

References

    1. Farmakidis C, Pasnoor M, Dimachkie MM, Barohn RJ. Treatment of Myasthenia Gravis. Neurol Clin. 2018;36(2):311–37. - PMC - PubMed
    1. Baggi F, Andreetta F, Maggi L, Confalonieri P, Morandi L, Salerno F, et al. Complete stable remission and autoantibody specificity in myasthenia gravis. Neurology. 2013;80(2):188–95. - PubMed
    1. Abuzinadah AR, Jabari D, Jawdat O, Pasnoor M, Glenn M, Herbelin L, et al. Satisfactory Response With Achieving Maintenance Low-Dose Prednisone in Generalized Myasthenia Gravis. J Clin Neuromuscul Dis. 2018;20(2):49–59. - PMC - PubMed
    1. Sanders DB, Wolfe GI, Benatar M, Evoli A, Gilhus NE, Illa I, et al. International consensus guidance for management of myasthenia gravis: Executive summary. Neurology. 2016;87(4):419–25. - PMC - PubMed
    1. Dicker RC, Coronado F, Koo D, Parrish RG. Principles of Epidemiology in Public Health Practice, 3rd Edition. Measures of Risk. 2006:3–13.

Publication types